Full-Time

Professional Aesthetic Consultant

Confirmed live in the last 24 hours

Revance

Revance

501-1,000 employees

Biotechnology company for aesthetic solutions

Compensation Overview

$90k - $105kAnnually

+ Uncapped Commissions

Senior, Expert

Grand Rapids, MI, USA

Ability to travel up to 50%+

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Lead Generation
Requirements
  • Master’s degree
  • Bachelor’s degree & 2 years of sales experience
Responsibilities
  • Strategically manages the territory to meet or exceed sales objectives.
  • Responsible for lead generation through direct contact with customers in assigned area.
  • Maintains effective customer relations, develops opportunities for growth within an existing customer base, and assures market penetration and profitability while achieving sales forecasts.
  • Delivers sales results per assigned quarterly goals, and have primary responsibility for area metrics, issues and customers.
  • Maintains a pipeline of opportunities to meet or exceed sales objectives.
  • Provides and filters key market insights back to sales and marketing management.
  • Maintains accurate reporting, records and files necessary for proper management of territory.
  • Positively represents Revance throughout customer locations.
  • Actively participates in sales meetings, conference calls, and other necessary business meetings.
  • Demonstrates honesty and integrity while modeling behaviors consistent with company standards, and adheres to all sales policies and procedures.
Desired Qualifications
  • 5+ years of sales/account management experience.
  • History of meeting and exceeding sales objectives.
  • Experience in medical aesthetics, dermatology, or plastic surgery.
  • Launch experience.
  • Experience in buy and bill or cash pay medicine.
  • Advanced business acumen; understands competitors, influencers and industry trends.
  • Ability to work in a launch or fast-paced, highly visible and dynamic environment.
  • Strong knowledge of analytics, budgeting and key revenue drivers; able to leverage data to target and prioritize opportunities.
  • Demonstrates perseverance, resiliency, and positive ‘can-do’ attitude.
  • Possess a self-starter, entrepreneurial spirit, with extreme accountability/ownership for territory results.
  • Advanced presentation skills; ability to engage and meet the needs of various audiences.

Revance Therapeutics, Inc. specializes in biotechnology with a focus on aesthetic and therapeutic solutions. The company primarily offers neuromodulators and dermal fillers, which are popular for minimally invasive cosmetic procedures. Neuromodulators, like botulinum toxin type A, help reduce wrinkles and treat muscle movement disorders, while dermal fillers restore volume and smooth facial lines. Revance is also exploring therapeutic uses for its products to enhance patient experiences in treating muscle movement and pain disorders. Additionally, the company has expanded into the fintech sector with the acquisition of HintMD, a platform that simplifies payment processes for aesthetic practices. This integration allows Revance to offer a comprehensive suite of services to support aesthetic practitioners. Unlike its competitors, Revance focuses on differentiated products and improved patient outcomes, aiming to lead the premium aesthetics market.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Revance's collaboration with Dermata could revolutionize botulinum toxin delivery.
  • The acquisition of HintMD enhances payment processes, boosting customer satisfaction.
  • Alpine Associates' $21.61 million investment shows strong investor confidence.

What critics are saying

  • A class action lawsuit for alleged securities fraud could harm Revance's reputation.
  • Evolus's targeting of younger demographics may capture market share from Revance.
  • Minimum purchase obligations under the Distribution Agreement pose financial risks.

What makes Revance unique

  • Revance focuses on innovative aesthetic and therapeutic solutions in the biotechnology sector.
  • The company integrates fintech solutions to streamline payment processes for aesthetic practices.
  • Revance is developing needle-free botulinum toxin delivery systems with Dermata.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

401(k) Company Match

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-1%

2 year growth

6%
Finimize
Mar 5th, 2025
Evolus Celebrates Strong Demand For Jeuveau Wrinkle Treatment

Evolus has strategically targeted a younger audience with its wrinkle treatment Jeuveau, setting itself apart from competitors like Revance and AbbVie, which usually focus on clients in their 40s.

GlobeNewswire
Feb 4th, 2025
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of "a material breach by the other party."

PR Newswire
Jan 31st, 2025
Revance Stockholders Urged To Tender Their Shares In Support Of Crown Transaction By The February 4Th Deadline

Crown offer of $3.65 per share is the only offer available to Revance stockholders. Crown offer unanimously approved by the Revance Board of Directors. Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender

Bizjournals
Jan 30th, 2025
Revance Therapeutics to Go Private at $3.65

Revance Therapeutics is set to go private with Crown Laboratories by Feb. 6. Crown has increased its offer to $3.65 per share, a 17% rise from the previous $3.10 offer. The deal, endorsed by Revance's board, is the only fully-financed offer available. The initial $6.66 offer was paused due to a breach with Teoxane, but a settlement has been reached. Revance's shares were trading at $3.63, with a 52-week range of $2.30-$7.56. The offer is valid until Feb. 4.

Teknovation
Jan 27th, 2025
News & Notes | Acting Administrator Of National Nuclear Security Administration Has Oak Ridge Ties

From Washington, DC but with Oak Ridge ties: Teresa Robbins has been named as the Acting Administrator of the National Nuclear Security Administration (NNSA). Prior to this, she served as... The post News Notes | Acting Administrator of National Nuclear Security Administration has Oak Ridge ties appeared first on Teknovation.biz.